Monday, June 13, 2016

Alpine Immune Sciences Scores $48M

Seattle-based Alpine Immune Sciences, a startup developing protein-based immunotherapy products, has raised $48M in its Series A round, the company said this morning. The funding was led by Orbimed Advisors, and also included Frazier Healthcare Partners and Alpine BioVentures, which seed funded and founded Alpine Immune Sciences. Mitchell H. Gold of Alpine BioVentures becomes Chairman and acting CEO of the company as a result of the funding, with Jay Venkatesan joining the board and serving as President; Frazier's Jamie Topper and OrbiMed's Peter Thompson also join the board.